Neonatal stroke

Neonatal stroke, similar to a stroke that occurs in adults, is defined as a disturbance to the blood supply of the developing brain in the first 28 days of life.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Neonatal stroke, similar to a stroke that occurs in adults, is defined as a disturbance to the blood supply of the developing brain in the first 28 days of life. This description includes both ischemic events, which result from a blockage of vessels, and hypoxic events, which result from a lack of oxygen to the brain tissue, as well as some combination of the two.

One treatment with some proven benefits is hypothermia, but it may be most beneficial in conjunction with pharmacological agents. Well-designed clinical trials for stroke treatment in neonates are lacking, but some current studies involve the transplantation of neural stem cells and umbilical cord stem cells; it is not yet known if this therapy is likely to be successful.

Neonatal strokes may lead to cerebral palsy, learning difficulties, or other disabilities. A neonatal stroke occurs in approximately 1 in 4000 births, but is likely much higher due to the lack of noticeable symptoms.

Presentation

A neonatal stroke is one that occurs in the first 28 days of life, though a late presentation is not uncommon (as contrasted with perinatal stroke, which occurs from 28 weeks of gestation through the first 7 days of life). 80% of neonatal strokes are ischemic, and their presentation is varied, making diagnosis very difficult.

The most common manifestation of neonatal strokes is seizures, but other manifestations include lethargy, hypotonia, apnoea, and hemiparesis. Seizures can be focal or generalized in nature. Stroke accounts for about 10% of seizures in term neonates.

Therapeutic hypothermia

Hypothermia treatment induced by head cooling or systemic cooling administered within six hours of birth for 72 hours has proven beneficial in reducing death and neurological impairments at 18 months of age. This treatment does not completely protect the injured brain and may not reduce the risk of death in the most severely hypoxic-ischemic neonates, and has also not been proven beneficial in preterm infants.

Combined therapies of hypothermia and pharmacological agents or growth factors to improve neurological outcomes are most likely the next direction for damaged neonatal brains, such as after a stroke.

Other treatments

A successful use of urokinase in a newborn with an aortic clot has been reported, but the bleeding risks associated with thrombolytic agents are still unclear. Heparin, an anticoagulant, treatments have been used in cases of cerebro-venous sinus thrombosis (CVST) in order to stop thrombosis extension and recurrence, to induce thrombosis resolution, and to prevent further brain damage.

In the case of extremely high intracranial pressure, surgical removal of the hematoma may be beneficial.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1371094775 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.